Loading stock data…
AbbVie Inc. (ABBV)
$259.36+2.44 (+0.95%)
After Hours$258.50-0.86 (-0.33%)· Last close Jul 24
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AbbVie Inc. in the Healthcare sector is trading at $259.36 with a market capitalization of $448.2B. Wall Street consensus targets $267.79 (28 analysts), implying a +3.2% move over the next 12 months. The stock is currently near its 52-week high of $261.64, remaining 17.5% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.00B↓ | $16.62B↑ | $15.78B↑ | $15.42B↑ | $13.34B |
| Gross Profit | $10.78B↓ | $12.07B↑ | $10.47B↓ | $11.08B↑ | $9.34B |
| Operating Income | $4.73B↓ | $5.81B↑ | $4.58B↓ | $5.72B↑ | $3.98B |
| Net Income | $695.00M↓ | $1.82B↑ | $186.00M↓ | $938.00M↓ | $1.29B |
Peer Comparison
JNJUNHPFE
Fundamentals
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$448.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
123.74
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.60%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.61%
Volume
Today's trading volume
3.05M
Recent News
J&J's Innovative Medicine Unit Proves Its Resilience in Q2
JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HDV Delivers 3.1% Yield While Beating SPY Year to Date by 9 Points
HDV quietly stacks a 3.1% income stream on top of equity gains that have left the S&P 500 in the dust this year, but the fund's concentrated sector bets carry a catch that most yield-seekers overlook.
Best Monthly Dividend ETFs for Consistent Income
If you're looking for more frequent payouts, you can still enjoy the benefits of low fees and broad diversification, thanks to these top monthly dividend ETFs.
I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation
When quality goes on sale, it's time to back up the truck.